Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Fertility Treatment in IBD: Insights From the WIsDoM Cohort Eugenia Shmidt, MD, Zoë Gottlieb, MD

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

What Comprehensive Disease Control Means for IBD, With David Rubin, MD David Rubin, MD

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Latest News

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

A gastroenterologist explains why treating bowel inflammation alone isn't enough to call inflammatory bowel disease "controlled."

News All Time

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

When Abdominal Pain Is Actually a Food Allergy: A GI Workup Brian Lacy, MD, PhD

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A Alex Hillenbrand

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

The HCPFive: Top News for Healthcare Providers from the Week of 06/21 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients Alex Hillenbrand

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

Q2 2026 Recap: Gastroenterology News & Updates Abigail Brooks, MA

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

First Half 2026 Recap: Gastroenterology Alex Hillenbrand

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

Recommended News For You

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?

Revolutionary Cancer Tx Could Transform Autoimmune Disease

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

Recommended Articles For You

Community Survivorship Networks for Long-Term Cancer Wellness 

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence 

How to Prevent Tumor Lysis Syndrome in Cancer Patients 

Clinical Pathways in Hematology in Clinical Decision-Making 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

2.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

3.

Kate Middleton Announces Major Cancer Update

4.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

5.

Future of Lab-Developed Tests Still Taking Shape

1.

How Cancer Cells Evade Immune Destruction and the Fight Back

2.

Menstrual Blood Changes in Iron-Deficiency States: Clinical Insights and Evidence-Based Management

3.

HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment

4.

The Future of Hematology: Innovations Every Doctor Should Know

5.

Reproductive Aging and Fertility Preservation Timing

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

How Nutrition Can Support Patients During Cancer Care

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

4.

Recognizing General Warning Signs of Cancer

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot